

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated antibody that ~~comprises at least one amino acid sequence as listed in SEQ ID NOs:1-8 comprising~~
a V_H domain having a CDR1 comprising the sequence set forth in SEQ ID NO:6,
a CDR2 comprising the sequence set forth in SEQ ID NO:7, and a CDR3 comprising the
sequence set forth in SEQ ID NO:8; and
a V_L domain having a CDR1 comprising the sequence set forth in SEQ ID NO:3,
a CDR2 comprising the sequence set forth in SEQ ID NO:4, and a CDR3 comprising the
sequence set forth in SEQ ID NO:5,
wherein the antibody ~~which~~ can bind to Factor IX/Factor IXa and increase the
procoagulation activity of ~~FIXa~~ Factor IXa.
- 2-7. (Canceled)
8. (Currently amended) The isolated antibody according to claim 1, ~~7,~~
wherein the antibody V_H domain comprises the sequence set forth in SEQ ID NO: 1 and
the V_L domain comprises the sequence set forth in SEQ ID NO:2.
9. (Currently amended) The isolated antibody according to claim 1, ~~which~~
wherein the antibody is an IgG-antibody.
10. (Currently amended) The isolated antibody according to claim 1, ~~which~~
wherein the antibody is a monoclonal antibody.
11. (Currently amended) The isolated antibody according to claim 1, ~~which~~
wherein the antibody is an antibody fragment.

12. (Currently amended) The isolated antibody according to claim 1, ~~which wherein the antibody~~ is a recombinant antibody.

13. (Currently amended) The isolated antibody according to claim 12, ~~which wherein the antibody~~ is a single chain antibody.

14. (Currently amended) The isolated antibody according to claim 1, ~~which wherein the antibody~~ is a humanized antibody.

15. (Currently amended) The isolated antibody of claim 1, wherein the antibody is labeled.

16-21. (Canceled)

22. (Currently amended) A pharmaceutical composition comprising an isolated antibody of claim 1 and a pharmaceutically acceptable carrier and/or diluent.

23. (Currently amended) The pharmaceutical composition comprising the isolated antibody of claim ~~8~~ 22, ~~wherein the antibody comprises at least one complement determining region (CDR), the at least one CDR comprising at least one amino acid sequence as listed in SEQ ID NOs:3-8.~~

24. (Currently amended) The pharmaceutical composition according to claim 23, further comprising a Factor selected from the group consisting of factor Factor IX, factor Factor IX α , IX α , factor Factor IX α IX α , and/or factor Factor IX, and combinations thereof.

25-27. (Canceled)

28. (New) The pharmaceutical composition according to claim 22, further comprising a Factor selected from the group consisting of Factor IX, Factor IX α , Factor IX α β , and combinations thereof.